A Safety Study of SGN-CD19A for Leukemia and Lymphoma

Clinical trial NCT01786096 · COMPLETED

Trial details

NCT number: NCT01786096
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Burkitt Lymphoma Precursor B-cell Lymphoblastic Leukemia-Lymphoma

Start date: 2013-02-01
Primary completion: 2017-05-30
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.